Singapore's Health Sciences Authority (HSA) has approved QINLOCK® (ripretinib) for the treatment of patients with 4th line GIST QINLOCK significantly reduced the risk of disease progression or death by 85% and showed clinically meaningful overall survival in the INVICTUS Phase 3 Study1,2 SINGAPORE, May 8, 2023 /PRNewswire/ Independent biopharmaceutical company Specialised Therapeutics Asia (ST) is pleased to.
NEW THERAPY FOR RARE GASTROINTESTINAL STROMAL TUMOURS APPROVED IN SINGAPORE streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
QINLOCK® (ripretinib) now Medsafe approved for GIST patients in NZ QINLOCK now being considered by PHARMAC for reimbursement Data from the INVICTUS Phase 3 study shows QINLOCK reduces risk of disease progression or death by 85%1, 2 SINGAPORE and AUCKLAND, New Zealand, Jan. 20, 2023 /PRNewswire/ Independent biopharmaceutical company Specialised Therapeutics Asia (ST) is pleased to announce.